Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status approved
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII X6Q56QN5QC
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abortion spontaneous18.01.04.0010.000783%Not Available
Actinic keratosis23.01.06.0010.001063%Not Available
Acute febrile neutrophilic dermatosis23.03.03.033; 01.02.01.0060.000112%Not Available
Acute hepatic failure09.01.03.0010.000112%Not Available
Acute leukaemia01.10.02.001; 16.01.02.0010.000280%Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.001567%Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.0010.000280%Not Available
Acute respiratory distress syndrome24.03.02.034; 10.02.01.067; 22.01.03.0010.000224%
Acute respiratory failure22.02.06.001; 14.01.04.0040.000280%Not Available
Agranulocytosis01.02.03.0010.000112%Not Available
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.000280%Not Available
Amenorrhoea21.01.02.001; 05.05.01.002--
Anaemia01.03.02.0010.004645%
Anaemia macrocytic01.03.02.002; 14.12.01.0020.000336%Not Available
Anaemia megaloblastic14.12.01.003; 01.03.02.003--Not Available
Angina unstable24.04.04.004; 02.02.02.0040.000112%Not Available
Apathy19.04.04.0020.000112%Not Available
Aphasia19.21.01.001; 17.02.03.0010.000168%
Aplastic anaemia01.03.03.0020.000168%Not Available
Arrhythmia02.03.02.0010.000168%Not Available
Arthralgia15.01.02.0010.000783%
Arthropathy15.01.01.0030.000582%Not Available
Ascites02.05.04.002; 09.01.05.003; 07.07.01.0010.000112%
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.0100.000168%Not Available
Atrial fibrillation02.03.03.0020.000336%
Atrophy08.03.04.001--Not Available
Azoospermia21.03.03.0010.000112%
The 1th Page    1 2 3 4 5    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene